Significant progress has been made in the past several years in improving the results of pancreatic islet transplantation for type 1 diabetics. Here at UCSF, we are very pleased with our success rate using a new enzyme that has helped to ensure islet viability through the transplant process.
Through the international Clinical Islet Transplant (CIT) Consortium, we are pursuing studies that will involve two sets of patients – those who have not been transplanted previously, and those who have received a kidney transplant and now have normal kidney function. In addition, we are conducting a single-center JDRF trial using new immunosuppressive agents that do not have the side effects of traditional anti-rejection drugs. These agents – Raptiva and Belatacept – have been effective in preventing islet rejection, and, in the case of Raptiva, a high percentage of patients achieve insulin independence after only one infusion. If you or a loved one have type 1 diabetes and have experienced poor glucose control despite intensive insulin therapy, we hope you’ll contact us to learn more about these studies: 415-353-8893; email@example.com